Details of the Drug

General Information of Drug (ID: DM8RZ9H)

• Drug Name: Eszopiclone
• Synonyms: Esopiclone; Estorra; Lunesta; Lunivia; Estorra (TN); Eszopiclone [USAN:INN]; KS-1055; SEP-0227018; SEP-0227108; SEP-190; SEP-225441; Eszopiclone (JAN/USAN/INN); [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; (plus)-Zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]

• Therapeutic Class: Hypnotics and Sedatives
• Affected Organisms: Humans and other mammals
• ATC Code:
  N05CF04: Eszopiclone
  N05CF: Benzodiazepine related drugs
  N05C: HYPNOTICS AND SEDATIVES
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 388.8
  Logarithm of the Partition Coefficient (xlogp); 0.5
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 278 mcgh/L [2]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h [2]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The clearance of drug is 184 mL/min in one pharmacokinetic study [2]
  Elimination: Only about 10% of an eszopiclone dose is found excreted in the urine as the parent drug [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6.1 hours [2]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1102 micromolar/kg/day [5]
  Vd: The volume of distribution (Vd) of drug is 89.9 L [6]
• Chemical Identifiers:
  Formula: C17H17ClN6O3
  IUPAC Name: [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
  Canonical SMILES: CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
  InChI: InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
  InChIKey: GBBSUAFBMRNDJC-INIZCTEOSA-N
• Cross-matching ID:
  PubChem CID: 969472
  ChEBI ID: CHEBI:53760
  CAS Number: 138729-47-2
  UNII: UZX80K71OE
  DrugBank ID: DB00402
  TTD ID: D06ZII
  INTEDE ID: DR0652
  ACDINA ID: D00250

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Agonist	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2E1 (CYP2E1) Main DME	DEVDYN7	CP2E1_HUMAN	Substrate	[9]
Cytochrome P450 2C8 (CYP2C8) Main DME	DES5XRU	CP2C8_HUMAN	Substrate	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Eszopiclone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Eszopiclone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[10]

Coadministration of a Drug Treating the Disease Different from Eszopiclone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Eszopiclone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[10]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Eszopiclone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[10]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Eszopiclone and Oliceridine.	Acute pain [MG31]	[11]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Eszopiclone caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[10]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Eszopiclone caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[12]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Eszopiclone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[13]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Eszopiclone caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[12]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Eszopiclone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[12]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Eszopiclone caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Eszopiclone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Eszopiclone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Chloramphenicol	DMFXEWT	Moderate	Decreased metabolism of Eszopiclone caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Eszopiclone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Eszopiclone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Eszopiclone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[10]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Eszopiclone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Tucatinib	DMBESUA	Major	Decreased metabolism of Eszopiclone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Eszopiclone caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[10]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Eszopiclone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[10]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Eszopiclone and Dihydrocodeine.	Chronic pain [MG30]	[16]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Olopatadine.	Conjunctiva disorder [9A60]	[17]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Propofol.	Corneal disease [9A76-9A78]	[18]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Eszopiclone and Alfentanil.	Corneal disease [9A76-9A78]	[11]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Eszopiclone and Remifentanil.	Corneal disease [9A76-9A78]	[11]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Eszopiclone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[19]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Eszopiclone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[20]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Ethanol.	Cystitis [GC00]	[17]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Eszopiclone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[12]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Eszopiclone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Eszopiclone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Esketamine.	Depression [6A70-6A7Z]	[19]
Primidone	DM0WX6I	Moderate	Increased metabolism of Eszopiclone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Eszopiclone caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Eszopiclone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Eszopiclone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Eszopiclone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Eszopiclone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Eszopiclone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Eszopiclone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Eszopiclone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Eszopiclone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Eszopiclone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[10]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Eszopiclone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[12]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Eszopiclone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[12]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Eszopiclone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[12]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Brimonidine.	Glaucoma [9C61]	[21]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Eszopiclone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[10]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Eszopiclone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[12]
Telaprevir	DMMRV29	Major	Decreased metabolism of Eszopiclone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[12]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Eszopiclone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[13]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Eszopiclone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[10]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Eszopiclone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Eszopiclone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Eszopiclone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Eszopiclone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Saquinavir	DMG814N	Major	Decreased metabolism of Eszopiclone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Eszopiclone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Eszopiclone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Eszopiclone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Eszopiclone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Ritonavir	DMU764S	Major	Decreased metabolism of Eszopiclone caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Eszopiclone caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Conivaptan	DM1V329	Major	Decreased metabolism of Eszopiclone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[12]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Eszopiclone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[12]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Eszopiclone caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[12]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Eszopiclone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Ceritinib	DMB920Z	Major	Decreased metabolism of Eszopiclone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[12]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Eszopiclone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[10]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Eszopiclone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Eszopiclone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[12]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Eszopiclone caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[10]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Eszopiclone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[10]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[25]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Eszopiclone caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[26]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Flibanserin.	Mood disorder [6A60-6E23]	[27]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Thalidomide.	Multiple myeloma [2A83]	[28]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Eszopiclone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[10]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Eszopiclone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Eszopiclone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[29]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Eszopiclone caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Eszopiclone caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[30]
Modafinil	DMYILBE	Minor	Increased metabolism of Eszopiclone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[31]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Eszopiclone caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[14]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Eszopiclone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[16]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Apraclonidine.	Optic nerve disorder [9C40]	[21]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Eszopiclone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[32]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Eszopiclone and Pentazocine.	Pain [MG30-MG3Z]	[11]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Eszopiclone and Dextropropoxyphene.	Pain [MG30-MG3Z]	[33]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Eszopiclone and Butorphanol.	Pain [MG30-MG3Z]	[11]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Eszopiclone and Oxymorphone.	Pain [MG30-MG3Z]	[11]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Eszopiclone and Levorphanol.	Pain [MG30-MG3Z]	[11]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Eszopiclone and Dezocine.	Pain [MG30-MG3Z]	[11]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Eszopiclone and Nalbuphine.	Pain [MG30-MG3Z]	[11]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Eszopiclone and Buprenorphine.	Pain [MG30-MG3Z]	[34]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Eszopiclone and Hydrocodone.	Pain [MG30-MG3Z]	[11]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Eszopiclone and Meperidine.	Pain [MG30-MG3Z]	[11]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Eszopiclone and Oxycodone.	Pain [MG30-MG3Z]	[11]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Eszopiclone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[35]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Eszopiclone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[36]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Eszopiclone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[12]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Eszopiclone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[10]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Eszopiclone caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Eszopiclone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[10]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Eszopiclone caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[10]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Eszopiclone caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[10]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Eszopiclone and Fentanyl.	Sensation disturbance [MB40]	[11]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Eszopiclone and Sufentanil.	Sensation disturbance [MB40]	[11]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Eszopiclone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[12]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Eszopiclone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[24]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Eszopiclone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Armodafinil	DMGB035	Minor	Increased metabolism of Eszopiclone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[31]
LEE011	DMMX75K	Moderate	Decreased metabolism of Eszopiclone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Eszopiclone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[37]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Eszopiclone and Tizanidine.	Tonus and reflex abnormality [MB47]	[38]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Eszopiclone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[10]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Eszopiclone 1 mg tablet	1 mg	Oral Tablet	Oral
Eszopiclone 2 mg tablet	2 mg	Oral Tablet	Oral
Eszopiclone 3 mg tablet	3 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7429).
• [2] Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1609-18. doi: 10.1517/17425255.2012.741588. Epub 2012 Nov 6.
• [3] BDDCS applied to over 900 drugs
• [4] FDA Approved Drug Products: Lunesta (eszopiclone) oral tablets
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] FDA review, Eszopiclone
• [7] New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
• [8] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [9] Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
• [10] Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
• [11] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [12] Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
• [13] Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
• [14] Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P "Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism." Drug Metab Dispos 27 (1999): 1068-73. [PMID: 10460808]
• [15] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [16] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [18] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
• [19] Cerner Multum, Inc. "Australian Product Information.".
• [20] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [21] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [22] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [23] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [24] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [25] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [26] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [27] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [28] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [29] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [30] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [31] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [32] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [33] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [34] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [35] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [36] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [37] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [38] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.